


**Vaccines Market By Technology Type (Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Others), By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP), Polio, Hepatitis, Other Indications), By End User (Pediatric, Adults, Travelers): Global Opportunity Analysis and Industry Forecast, 2024-2035**

Market Report | 2024-04-01 | 350 pages | Allied Market Research

**AVAILABLE LICENSES:**

- Cloud Access License \$3840.00
- Business User License \$6090.00
- Enterprise License \$10500.00

**Report description:**

The vaccine market was valued at \$43.2 billion in 2023 and is projected to reach \$90.7 billion by 2035, registering a CAGR of 6.4% from 2024 to 2035. A vaccine is a biological preparation that provides immunity to a particular infectious disease. It typically contains weakened or inactive forms of the pathogen, its toxins, or surface proteins, which stimulate the immune system to recognize and remember the pathogen. When people are vaccinated, their immune system responds by producing antibodies and activating immune cells specific to that pathogen. This creates a defense mechanism within the body, so if a person is later exposed to the actual infectious agent, the immune system can quickly recognize and destroy it, preventing or reducing the severity of the disease. Vaccines have been instrumental in controlling and eradicating many deadly diseases throughout history, making them one of the most significant advancements in modern medicine. The growth of the vaccine market is primarily driven by rise in prevalence of diseases, such as influenza, pneumococcal disease, HPV, and other infections, requiring administration of vaccines. For instance, in 2023, Centers for Disease Control and Prevention (CDC) estimated that 31 million people were sick with flu. In addition, government investment in vaccine research and development, manufacturing infrastructure, and public immunization programs significantly impacts the vaccine market. Public-private partnerships, grants, tax

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scott-international.com](mailto:support@scott-international.com)

[www.scott-international.com](http://www.scott-international.com)

incentives, and regulatory frameworks incentivize vaccine development and ensure safety, efficacy, and quality standards. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), play pivotal roles in evaluating and approving vaccines for licensure, which influences market access and adoption. However, the high development costs, complex manufacturing processes, and stringent regulatory requirements contribute to the high prices of vaccines, limiting affordability, especially in low- and middle-income countries (LMICs) which may restrain the market growth. In contrast, due to ongoing advancements in biotechnology, genomics, and immunology, there is an opportunity to expand disease prevention and control through the development of new and improved vaccines. Emerging infectious diseases, antimicrobial resistance, and re-emerging pathogens underscore the need for innovative vaccine solutions to address unmet medical needs and mitigate public health threats. The vaccine market is segmented on the basis of technology type, indication, end user, and region. By technology type, the market is categorized into recombinant and conjugate vaccines, live attenuated vaccines, inactivated vaccines, toxoid vaccines, and others. As per indication, the market is divided into pneumococcal disease, influenza, human papilloma virus, meningococcal disease, rotavirus, varicella, measles, mumps, and rubella, diphtheria, pertussis, and tetanus (DTP), polio, hepatitis, and other indications. Depending on end user, the market is categorized into pediatric, adults, and travelers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA). Major key players that operate in the global vaccine market are Merck & Co., Inc., Pfizer, Sanofi, Serum Institute of India Pvt. Ltd., Bavarian Nordic, CSL Limited, Emergent Bio Solutions Inc., GlaxoSmithKline plc., Zhi Fei Biological, and Bharat Biotech. The key players operating in the market have adopted clinical trial, product launch, product approval, and expansion as their key strategies to expand their product portfolio.

#### Key Benefits for Stakeholders

- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccines market analysis from 2023 to 2035 to identify the prevailing vaccines market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the vaccines market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global vaccines market trends, key players, market segments, application areas, and market growth strategies. Additional benefits you will get with this purchase are:
  - Quarterly Update and\* (only available with a corporate license, on listed price)
  - 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  - Free Upcoming Version on the Purchase of Five and Enterprise User License.
  - 16 analyst hours of support\* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  - 15% Free Customization\* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  - Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  - Free Updated report if the report is 6-12 months old or older.
  - 24-hour priority response\*
  - Free Industry updates and white papers. Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
  - Regulatory Guidelines
  - Additional company profiles with specific to client's interest
  - Additional country or region analysis- market size and forecast

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Expanded list for Company Profiles
  - Historic market data
  - Key player details (including location, contact details, supplier/vendor network etc. in excel format)
- Key Market Segments
- By Technology Type
- Inactivated Vaccines
  - Toxoid Vaccines
  - Others
  - Recombinant and Conjugate Vaccines
  - Live Attenuated Vaccines
- By Indication
- Pneumococcal Disease
  - Influenza
  - Human Papilloma Virus
  - Meningococcal Disease
  - Rotavirus
  - Varicella
  - Measles, Mumps, and Rubella
  - Diphtheria, Pertussis, and Tetanus (DTP)
  - Polio
  - Hepatitis
  - Other Indications
- By End User
- Pediatric
  - Adults
  - Travelers
- By Region
- North America
  - U.S.
  - Canada
  - Mexico
  - Europe
  - Germany
  - France
  - UK
  - Italy
  - Spain
  - Rest of Europe
  - Asia-Pacific
  - Japan
  - China
  - India
  - Australia
  - South Korea
  - Rest of Asia-Pacific
  - LAMEA
  - Brazil

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- CSL Limited
- Emergent Bi
- o Solutions Inc.
- GlaxoSmithKline Plc.
- Merck & Co., Inc.
- Pfizer
- Sanofi
- Serum Institute of India Pvt. Ltd.
- Bavarian Nordic
- Zhi Fei Biological
- Bharat Biotech

## **Table of Contents:**

### CHAPTER 1: INTRODUCTION

- 1.1. Report description
- 1.2. Key market segments
- 1.3. Key benefits to the stakeholders
- 1.4. Research methodology
  - 1.4.1. Primary research
  - 1.4.2. Secondary research
  - 1.4.3. Analyst tools and models

### CHAPTER 2: EXECUTIVE SUMMARY

- 2.1. CXO perspective

### CHAPTER 3: MARKET OVERVIEW

- 3.1. Market definition and scope
- 3.2. Key findings
  - 3.2.1. Top impacting factors
  - 3.2.2. Top investment pockets
- 3.3. Porter's five forces analysis
- 3.4. Market dynamics
  - 3.4.1. Drivers
  - 3.4.2. Restraints
  - 3.4.3. Opportunities

### CHAPTER 4: VACCINES MARKET, BY TECHNOLOGY TYPE

- 4.1. Overview
  - 4.1.1. Market size and forecast
- 4.2. Recombinant and Conjugate Vaccines
  - 4.2.1. Key market trends, growth factors and opportunities
  - 4.2.2. Market size and forecast, by region
  - 4.2.3. Market share analysis by country
- 4.3. Live Attenuated Vaccines
  - 4.3.1. Key market trends, growth factors and opportunities
  - 4.3.2. Market size and forecast, by region

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 4.3.3. Market share analysis by country
  - 4.4. Inactivated Vaccines
    - 4.4.1. Key market trends, growth factors and opportunities
    - 4.4.2. Market size and forecast, by region
    - 4.4.3. Market share analysis by country
  - 4.5. Toxoid Vaccines
    - 4.5.1. Key market trends, growth factors and opportunities
    - 4.5.2. Market size and forecast, by region
    - 4.5.3. Market share analysis by country
  - 4.6. Others
    - 4.6.1. Key market trends, growth factors and opportunities
    - 4.6.2. Market size and forecast, by region
    - 4.6.3. Market share analysis by country
- CHAPTER 5: VACCINES MARKET, BY INDICATION**
- 5.1. Overview
    - 5.1.1. Market size and forecast
  - 5.2. Pneumococcal Disease
    - 5.2.1. Key market trends, growth factors and opportunities
    - 5.2.2. Market size and forecast, by region
    - 5.2.3. Market share analysis by country
  - 5.3. Influenza
    - 5.3.1. Key market trends, growth factors and opportunities
    - 5.3.2. Market size and forecast, by region
    - 5.3.3. Market share analysis by country
  - 5.4. Human Papilloma Virus
    - 5.4.1. Key market trends, growth factors and opportunities
    - 5.4.2. Market size and forecast, by region
    - 5.4.3. Market share analysis by country
  - 5.5. Meningococcal Disease
    - 5.5.1. Key market trends, growth factors and opportunities
    - 5.5.2. Market size and forecast, by region
    - 5.5.3. Market share analysis by country
  - 5.6. Rotavirus
    - 5.6.1. Key market trends, growth factors and opportunities
    - 5.6.2. Market size and forecast, by region
    - 5.6.3. Market share analysis by country
  - 5.7. Varicella
    - 5.7.1. Key market trends, growth factors and opportunities
    - 5.7.2. Market size and forecast, by region
    - 5.7.3. Market share analysis by country
  - 5.8. Measles, Mumps, and Rubella
    - 5.8.1. Key market trends, growth factors and opportunities
    - 5.8.2. Market size and forecast, by region
    - 5.8.3. Market share analysis by country
  - 5.9. Diphtheria, Pertussis, and Tetanus (DTP)
    - 5.9.1. Key market trends, growth factors and opportunities
    - 5.9.2. Market size and forecast, by region

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.9.3. Market share analysis by country
  - 5.10. Polio
    - 5.10.1. Key market trends, growth factors and opportunities
    - 5.10.2. Market size and forecast, by region
    - 5.10.3. Market share analysis by country
  - 5.11. Hepatitis
    - 5.11.1. Key market trends, growth factors and opportunities
    - 5.11.2. Market size and forecast, by region
    - 5.11.3. Market share analysis by country
  - 5.12. Other Indications
    - 5.12.1. Key market trends, growth factors and opportunities
    - 5.12.2. Market size and forecast, by region
    - 5.12.3. Market share analysis by country
- CHAPTER 6: VACCINES MARKET, BY END USER

- 6.1. Overview
  - 6.1.1. Market size and forecast
- 6.2. Pediatric
  - 6.2.1. Key market trends, growth factors and opportunities
  - 6.2.2. Market size and forecast, by region
  - 6.2.3. Market share analysis by country
- 6.3. Adults
  - 6.3.1. Key market trends, growth factors and opportunities
  - 6.3.2. Market size and forecast, by region
  - 6.3.3. Market share analysis by country
- 6.4. Travelers
  - 6.4.1. Key market trends, growth factors and opportunities
  - 6.4.2. Market size and forecast, by region
  - 6.4.3. Market share analysis by country

CHAPTER 7: VACCINES MARKET, BY REGION

- 7.1. Overview
  - 7.1.1. Market size and forecast By Region
- 7.2. North America
  - 7.2.1. Key market trends, growth factors and opportunities
  - 7.2.2. Market size and forecast, by Technology Type
  - 7.2.3. Market size and forecast, by Indication
  - 7.2.4. Market size and forecast, by End User
  - 7.2.5. Market size and forecast, by country
    - 7.2.5.1. U.S.
      - 7.2.5.1.1. Market size and forecast, by Technology Type
      - 7.2.5.1.2. Market size and forecast, by Indication
      - 7.2.5.1.3. Market size and forecast, by End User
    - 7.2.5.2. Canada
      - 7.2.5.2.1. Market size and forecast, by Technology Type
      - 7.2.5.2.2. Market size and forecast, by Indication
      - 7.2.5.2.3. Market size and forecast, by End User
    - 7.2.5.3. Mexico
      - 7.2.5.3.1. Market size and forecast, by Technology Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

[www.scotts-international.com](http://www.scotts-international.com)

- 7.2.5.3.2. Market size and forecast, by Indication
- 7.2.5.3.3. Market size and forecast, by End User
- 7.3. Europe
  - 7.3.1. Key market trends, growth factors and opportunities
  - 7.3.2. Market size and forecast, by Technology Type
  - 7.3.3. Market size and forecast, by Indication
  - 7.3.4. Market size and forecast, by End User
  - 7.3.5. Market size and forecast, by country
    - 7.3.5.1. Germany
      - 7.3.5.1.1. Market size and forecast, by Technology Type
      - 7.3.5.1.2. Market size and forecast, by Indication
      - 7.3.5.1.3. Market size and forecast, by End User
    - 7.3.5.2. France
      - 7.3.5.3.2. Market size and forecast, by Indication
      - 7.3.5.3.3. Market size and forecast, by End User
    - 7.3.5.4. Italy
      - 7.3.5.4.1. Market size and forecast, by Technology Type
      - 7.3.5.4.2. Market size and forecast, by Indication
      - 7.3.5.4.3. Market size and forecast, by End User
    - 7.3.5.5. Spain
      - 7.3.5.5.1. Market size and forecast, by Technology Type
      - 7.3.5.5.2. Market size and forecast, by Indication
      - 7.3.5.5.3. Market size and forecast, by End User
    - 7.3.5.6. Rest of Europe
      - 7.3.5.6.1. Market size and forecast, by Technology Type
      - 7.3.5.6.2. Market size and forecast, by Indication
      - 7.3.5.6.3. Market size and forecast, by End User
- 7.4. Asia-Pacific
  - 7.4.1. Key market trends, growth factors and opportunities
  - 7.4.2. Market size and forecast, by Technology Type
  - 7.4.3. Market size and forecast, by Indication
  - 7.4.4. Market size and forecast, by End User
  - 7.4.5. Market size and forecast, by country
    - 7.4.5.1. Japan
      - 7.4.5.1.1. Market size and forecast, by Technology Type
      - 7.4.5.1.2. Market size and forecast, by Indication
      - 7.4.5.1.3. Market size and forecast, by End User
    - 7.4.5.2. China
      - 7.4.5.2.1. Market size and forecast, by Technology Type
      - 7.4.5.2.2. Market size and forecast, by Indication
      - 7.4.5.2.3. Market size and forecast, by End User
    - 7.4.5.3. India
      - 7.4.5.3.1. Market size and forecast, by Technology Type
      - 7.4.5.3.2. Market size and forecast, by Indication
      - 7.4.5.3.3. Market size and forecast, by End User
    - 7.4.5.4. Australia
      - 7.4.5.4.1. Market size and forecast, by Technology Type

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 7.4.5.4.2. Market size and forecast, by Indication
- 7.4.5.4.3. Market size and forecast, by End User
- 7.4.5.5. South Korea
  - 7.4.5.5.1. Market size and forecast, by Technology Type
  - 7.4.5.5.2. Market size and forecast, by Indication
  - 7.4.5.5.3. Market size and forecast, by End User
- 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Market size and forecast, by Technology Type
  - 7.4.5.6.2. Market size and forecast, by Indication
  - 7.4.5.6.3. Market size and forecast, by End User
- 7.5. LAMEA
  - 7.5.1. Key market trends, growth factors and opportunities
  - 7.5.2. Market size and forecast, by Technology Type
  - 7.5.3. Market size and forecast, by Indication
  - 7.5.4. Market size and forecast, by End User
  - 7.5.5. Market size and forecast, by country
    - 7.5.5.1. Brazil
      - 7.5.5.1.1. Market size and forecast, by Technology Type
      - 7.5.5.1.2. Market size and forecast, by Indication
      - 7.5.5.1.3. Market size and forecast, by End User
    - 7.5.5.2. Saudi Arabia
      - 7.5.5.2.1. Market size and forecast, by Technology Type
      - 7.5.5.2.2. Market size and forecast, by Indication
      - 7.5.5.2.3. Market size and forecast, by End User
    - 7.5.5.3. South Africa
      - 7.5.5.3.1. Market size and forecast, by Technology Type
      - 7.5.5.3.2. Market size and forecast, by Indication
      - 7.5.5.3.3. Market size and forecast, by End User
    - 7.5.5.4. Rest of LAMEA
      - 7.5.5.4.1. Market size and forecast, by Technology Type
      - 7.5.5.4.2. Market size and forecast, by Indication
      - 7.5.5.4.3. Market size and forecast, by End User

## CHAPTER 8: COMPETITIVE LANDSCAPE

- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product mapping of top 10 player
- 8.4. Competitive dashboard
- 8.5. Competitive heatmap
- 8.6. Top player positioning, 2023

## CHAPTER 9: COMPANY PROFILES

- 9.1. CSL Limited
  - 9.1.1. Company overview
  - 9.1.2. Key executives
  - 9.1.3. Company snapshot
  - 9.1.4. Operating business segments
  - 9.1.5. Product portfolio
  - 9.1.6. Business performance

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.1.7. Key strategic moves and developments
- 9.2. Emergent Bio Solutions Inc.
  - 9.2.1. Company overview
  - 9.2.2. Key executives
  - 9.2.3. Company snapshot
  - 9.2.4. Operating business segments
  - 9.2.5. Product portfolio
  - 9.2.6. Business performance
  - 9.2.7. Key strategic moves and developments
- 9.3. GlaxoSmithKline Plc.
  - 9.3.1. Company overview
  - 9.3.2. Key executives
  - 9.3.3. Company snapshot
  - 9.3.4. Operating business segments
  - 9.3.5. Product portfolio
  - 9.3.6. Business performance
  - 9.3.7. Key strategic moves and developments
- 9.4. Merck & Co., Inc.
  - 9.4.1. Company overview
  - 9.4.2. Key executives
  - 9.4.3. Company snapshot
  - 9.4.4. Operating business segments
  - 9.4.5. Product portfolio
  - 9.4.6. Business performance
  - 9.4.7. Key strategic moves and developments
- 9.5. Pfizer
  - 9.5.1. Company overview
  - 9.5.2. Key executives
  - 9.5.3. Company snapshot
  - 9.5.4. Operating business segments
  - 9.5.5. Product portfolio
  - 9.5.6. Business performance
  - 9.5.7. Key strategic moves and developments
- 9.6. Sanofi
  - 9.6.1. Company overview
  - 9.6.2. Key executives
  - 9.6.3. Company snapshot
  - 9.6.4. Operating business segments
  - 9.6.5. Product portfolio
  - 9.6.6. Business performance
  - 9.6.7. Key strategic moves and developments
- 9.7. Serum Institute of India Pvt. Ltd.
  - 9.7.1. Company overview
  - 9.7.2. Key executives
  - 9.7.3. Company snapshot
  - 9.7.4. Operating business segments
  - 9.7.5. Product portfolio

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.7.6. Business performance
- 9.7.7. Key strategic moves and developments
- 9.8. Bavarian Nordic
  - 9.8.1. Company overview
  - 9.8.2. Key executives
  - 9.8.3. Company snapshot
  - 9.8.4. Operating business segments
  - 9.8.5. Product portfolio
  - 9.8.6. Business performance
  - 9.8.7. Key strategic moves and developments
- 9.9. Zhi Fei Biological
  - 9.9.1. Company overview
  - 9.9.2. Key executives
  - 9.9.3. Company snapshot
  - 9.9.4. Operating business segments
  - 9.9.5. Product portfolio
  - 9.9.6. Business performance
  - 9.9.7. Key strategic moves and developments
- 9.10. Bharat Biotech
  - 9.10.1. Company overview
  - 9.10.2. Key executives
  - 9.10.3. Company snapshot
  - 9.10.4. Operating business segments
  - 9.10.5. Product portfolio
  - 9.10.6. Business performance
  - 9.10.7. Key strategic moves and developments

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**Vaccines Market By Technology Type (Recombinant and Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Others), By Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, and Rubella, Diphtheria, Pertussis, and Tetanus (DTP), Polio, Hepatitis, Other Indications), By End User (Pediatric, Adults, Travelers): Global Opportunity Analysis and Industry Forecast, 2024-2035**

Market Report | 2024-04-01 | 350 pages | Allied Market Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Cloud Access License	\$3840.00
	Business User License	\$6090.00
	Enterprise License	\$10500.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>